Related Experiment Video
Updated: Aug 5, 2026
15:17
Colorectal Cancer Cell Surface Protein Profiling Using an Antibody Microarray and Fluorescence Multiplexing
Published on: September 25, 2011
[New prognostic markers in colorectal cancer]
H J Nielsen1, N A Brünner, O Thorlacius-Ussing
1Hvidovre Hospital, kirurgisk gastroenterologisk afdeling.
Ugeskrift for Laeger
|August 28, 1998
Summary
Colorectal cancer survival remains low despite surgery. New biological markers may help select patients for adjuvant therapies, improving treatment strategies and outcomes.
Area of Science:
- Oncology
- Tumor Biology
- Cancer Therapeutics
Context:
- Colorectal cancer (CRC) has a poor five-year survival rate, even after curative surgery.
- Current adjuvant therapies (chemo-, radio-, immunotherapy) offer limited survival benefits for most CRC patients.
- Existing treatment strategies for CRC are insufficient, necessitating optimization of surgical and adjuvant approaches.
Purpose:
- To explore the need for improved treatment strategies in colorectal cancer.
- To investigate the potential of new biotechnological modalities for CRC treatment.
- To identify methods for selecting patients who will benefit from specific adjuvant therapies.
Summary:
- The majority of colorectal cancer patients do not achieve five-year survival, despite high rates of curative surgery.
- Adjuvant therapies currently have an insignificant impact on overall survival, highlighting treatment limitations.
- New biological markers are proposed for predicting prognosis and selecting patients for tailored adjuvant treatments, optimizing therapeutic strategies.
Impact:
- Optimizing adjuvant therapy selection can improve overall survival for colorectal cancer patients.
- Biotechnological advancements offer potential for novel CRC treatment modalities.
- Personalized medicine approaches using biological markers can enhance treatment efficacy and reduce unnecessary adjuvant interventions.
